A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder

References

• Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011;9:90
   PubMed Web of Science ®Google Scholar
• World Health Organization. The world health report 2004: Changing History. Annex Table 3: Burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for 2002. Geneva, Switzerland: World Health Organization, 2004. Available from: http://www.who.int/whr/2004/en/report04_en.pdf. [Last accessed 23 January 2014]
   Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Romera I, Perez V, Menchon JM, et al. Early switch strategy in patients with major depressive disorder: a double-blind, randomized study. J Clin Psychopharmacol 2012;32:479-86
   PubMed Web of Science ®Google Scholar
• Thase ME. Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 2003;64(2 Suppl):3-7
   Google Scholar
• Kelly K, Posternak M, Alpert JE. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin Neurosci 2008;10:409-18
   PubMedGoogle Scholar
• Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002;288:1403-9
   PubMed Web of Science ®Google Scholar
• Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004;65:959-65
   PubMed Web of Science ®Google Scholar
• Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:725-33
   PubMed Web of Science ®Google Scholar
• Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry 2011;68:1227-37
   PubMed Web of Science ®Google Scholar
• Guirguis-Blake J. Effectiveness of antidepressants compared with placebo for depression in primary care. Am Fam Physician 2010;82:42
   Google Scholar
• Auclair AL, Martel JC, Assie MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 2013;70:338-47
   PubMed Web of Science ®Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65
   PubMed Web of Science ®Google Scholar
• Montgomery S, Mansuy L, Ruth A, et al. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2013;74:363-9
   PubMed Web of Science ®Google Scholar
• Sambunaris A, Bose A, Gommoll C, et al. A Phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran ER in patients with major depressive disorder. J Clin Psychopharmacol 2014;34:47-56
   Google Scholar
• Asnis G, Bose A, Gommoll C, et al. The efficacy and safety of levomilnacipran SR 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase III, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013;74:242-8
   PubMed Web of Science ®Google Scholar
• Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40 mg and 80 mg in major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci 2014;39:40-9
   Google Scholar
• APA. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision. Washington, DC: American Psychiatric Association, 2000
   Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(20 Suppl):22-33
   Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(3 Suppl):89-95
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. “Clinical Global Impressions.” Rockville, MD: National Institute of Mental Health, p 218–22. DHEW Publication No. 76-338. 1976
   Google Scholar
• McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40
   PubMed Web of Science ®Google Scholar
• Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976) 2000;25:3130-9
   PubMed Web of Science ®Google Scholar
• Kenward MG, Molenberghs G, Thijs H. Pattern-mixture models with proper time dependence. Biometrika 2003;90:53-71
   Web of Science ®Google Scholar
• Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008;48:1680-9
   PubMed Web of Science ®Google Scholar
• Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002;287:1840-7
   PubMed Web of Science ®Google Scholar
• Sonawalla SB, Rosenbaum JF. Placebo response in depression. Dialogues Clin Neurosci 2002;4:105-13
   PubMedGoogle Scholar
• Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am j psychiatry 2013;170:723-33
   PubMed Web of Science ®Google Scholar
• Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 2002;5:193-7
   PubMed Web of Science ®Google Scholar
• Hooper M, Amsterdam J. Do clinical trials reflect drug potential? A review of FDA evaluation of new antidepressants. Poster Presented at the 39th Annual Meeting New Clinical Drug Evaluation Unit June 1–4; Boca Raton, FL, 1999
   Google Scholar
• Bridge JA, Birmaher B, Iyengar S, et al. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009;166:42-9
   PubMed Web of Science ®Google Scholar
• Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 2011;72:464-72
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009;19:34-40
   PubMed Web of Science ®Google Scholar
• Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003;28:552-7
   PubMed Web of Science ®Google Scholar
• Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004;161:2045-9
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007;41:189-206
   PubMed Web of Science ®Google Scholar
• Khan A, Leventhal RM, Khan SR, et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002;22:40-5
   PubMed Web of Science ®Google Scholar
• Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45
   PubMed Web of Science ®Google Scholar
• Robinson DS, Rickels K. Concerns about clinical drug trials. J Clin Psychopharmacol 2000;20:593-6
   Google Scholar
• Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-47
   PubMed Web of Science ®Google Scholar
• McGahuey CA, Delgado PL, Gelenberg AJ. Assessment of sexual dysfunction using the Arizona Sexual Experiences Scale (ASEX) and implications for the treatment of depression. Psychiat Ann 1999;29:39-45
   Web of Science ®Google Scholar